Komori
Kissei Pharmaceutical (4547) · RiskRestated

Supply stoppages caused by production equipment, raw materials and quality issues

First written in FY2016. 19 of 22 entries say "Restated". Latest entry: FY2024.

22entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2020-Q3RestatedFY2021-Q1 – FY2022-Q3RestatedFY2023-Q1 – FY20242016: 120162017: 220172018: 320182019: 420192020: 420202021: 120212022: 420222023: 220232024: 12024
Same theme, other companies

2 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2024RestatedAnnual report

    「Although we have established manufacturing and quality control systems in compliance with the latest laws, regulations, and guidelines, if quality issues require product recalls or other measures, business performance or financial condition may be affected.」

    While conducting quality control in accordance with laws, regulations, and guidelines, the risk of quality issues and product recalls has been reconfirmed.
  2. FY2024-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of supply disruptions caused by production facilities, raw materials, and quality issues.
  3. FY2023-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of supply disruptions caused by production facilities, raw materials, and quality issues.
  4. FY2023-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of supply disruptions caused by production facilities, raw materials, and quality issues.
  5. FY2023-Q1RestatedAnnual report

    「During the three-month period ended 30 June, there were no new risks that management recognizes as having the potential to materially affect the financial position, operating results or cash flows of the consolidated companies, and no material changes to the business risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of supply disruptions caused by production facilities, raw materials, and quality issues.
  6. FY2022SoftenedAnnual report

    「Although we have established manufacturing and quality control systems in compliance with the latest laws, regulations, and guidelines, if quality issues require product recalls or other measures, business performance or financial condition may be affected.」

    The previously disclosed risks of equipment failures, delays in obtaining raw materials, and shipment adjustments due to excess demand have been removed from this year’s description of quality risks, which now focuses on quality issues and product recalls.
  7. FY2022-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of supply disruptions caused by production facilities, raw materials, and quality issues.
  8. FY2022-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of supply disruptions caused by production facilities, raw materials, and quality issues.
  9. FY2021-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of supply disruptions caused by production facilities, raw materials, and quality issues.
  10. FY2021-Q1RestatedAnnual report

    「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of supply disruptions caused by production facilities, raw materials, and quality issues.
  11. FY2020WorsenedAnnual report

    「If manufacturing is delayed or suspended due to problems with production facilities or delays in obtaining raw materials, if quality issues require product recalls or other measures, or if supply cannot keep pace with product demand and shipment adjustments become unavoidable, business performance or financial condition may be affected.」

    In addition to the previously identified risks of equipment failures, delays in obtaining raw materials, and quality issues, the risk of shipment adjustments when demand exceeds supply has been added.
  12. FY2020-Q3RestatedAnnual report

    「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of supply disruptions caused by production facilities, raw materials, and quality issues.
  13. FY2020-Q2RestatedAnnual report

    「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of supply disruptions caused by production facilities, raw materials, and quality issues.
  14. FY2020-Q1RestatedAnnual report

    「There were no newly arising business or other risks during the cumulative consolidated period for the first quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of supply disruptions caused by production facilities, raw materials, and quality issues.
  15. FY2019RestatedAnnual report

    「If manufacturing is delayed or suspended due to problems with production facilities or delays in obtaining raw materials, or if quality issues require product recalls or other measures, business performance or financial condition may be affected.」

    The risk of manufacturing stoppages and product recalls due to equipment failures, delays in obtaining raw materials, and quality issues has been reconfirmed.
  16. FY2019-Q3RestatedAnnual report

    「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of supply disruptions caused by production facilities, raw materials, and quality issues.
  17. FY2019-Q2RestatedAnnual report

    「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of supply disruptions caused by production facilities, raw materials, and quality issues.
  18. FY2018RestatedAnnual report

    「If manufacturing is delayed or suspended due to problems with production facilities or delays in obtaining raw materials, or if quality issues require product recalls or other measures, business performance or financial condition may be affected.」

    The risk of manufacturing stoppages and product recalls due to equipment failures, delays in obtaining raw materials, and quality issues has been reconfirmed.
  19. FY2018-Q3RestatedAnnual report

    「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of supply disruptions caused by production facilities, raw materials, and quality issues.
  20. FY2018-Q2RestatedAnnual report

    「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the risk of supply disruptions caused by production facilities, raw materials, and quality issues.
  21. FY2017RestatedAnnual report

    「If manufacturing is delayed or suspended due to problems with production facilities or delays in obtaining raw materials, or if quality issues require product recalls or other measures, business performance or financial condition may be affected.」

    The risk of manufacturing stoppages and product recalls due to production equipment, raw materials, and quality issues has been reconfirmed.
  22. FY2016First statedAnnual report

    「If manufacturing is delayed or suspended due to problems with production facilities or delays in obtaining raw materials, or if quality issues require product recalls or other measures, business performance or financial condition may be affected.」

    Equipment failures, delays in obtaining raw materials, quality issues, and product recalls are identified as risks affecting supply and business performance.
Moved together

"Healthcare System Reform, Healthcare Cost Containment, and Intensifying Market Competition" moved the same way as this thread, in the same document, in 2 of its 22 moves.

222★123
  1. ★This thread
  2. 1Healthcare System Reform, Healthcare Cost Containment, and Intensifying Market Competition2×
  3. 2Uncertainty in New Drug Research and Development2×
  4. 3Impact on business performance from drug price revisions and generic-drug promotion measures2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Kissei Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Supply stoppages caused by production equipment, raw materials and quality issues | KISSEI PHARMACEUTICAL CO.,LTD. (4547) | Komori